Table 1 Characteristics of 15 RCTs included
From: Bisphosphonates therapy for osteoarthritis: a meta-analysis of randomized controlled trials
Authors | Study design | Number of patients | Age (year) | Affected joint | Diagnostic criteria | Duration (month) | Outcome meature | Drugs |
|---|---|---|---|---|---|---|---|---|
Neogi et al. (2008) | Randomised case–control | 200 | 65.8 ± 6.1 66.1 ± 6.4 | Spine | Radiographs | 24 | OST, DSN | Alendronate VS placebo |
Rossini et al. (2015) | Double-blind randomized | 80 | 66 ± 6 | Knee | Radiographs | 3 | WOMAC, VAS | Clodronate VS placebo |
Laslett et al. (2014) | Observational cohort study | 323 | 59.8 ± 8 66.7 ± 7.4 | Knee | Radiographs | 60 | VAS, WOMAC, JSW | Bisphosphonates used VS Non-users |
Nishii et al. (2013) | Non-blinded randomised | 42 | 54.7 ± 8.5 58.3 ± 8.8 | Hip | Radiographs | 24 | WOMAC, VAS, JSW | Alendronate VS calcium lactate |
Arti and Azemi (2012) | Double-blind randomized | 130 | 60.9 ± 9.9 | Knee | Radiographs | 3 | WOMAC | Alendronate VS glucosamine |
Laslett et al. (2012) | Double-blind randomised | 53 | 64.2 ± 8.2 60.4 ± 7.3 | Knee | Radiographs | 12 | VAS,KOOS; | Zoledronic VS placebo |
Saviola et al. (2012) | Non-randomised case control | 29 | 60.0 ± 7.1 63.5 ± 7.4 | Hand | Radiographs | 24 | VAS, HS, NOSPJ | Clodronate VS HCQ |
Fujita et al. (2011) | Randomised case–control | 38 | 69 ± 8 68 ± 9 | Spine, knee | Radiographs | 6 | VAS, SF-36 | Risedronate VS Elcatonin |
Rossini et al. (2009) | Partially blinded randomised | 150 | 64.7 ± 7.4 65.2 ± 6.9 | Knee | Radiographs | 18 | VAS, LI | Clodronate VS Hyaluronic acid |
Fujita et al. (2009) | Non-randomised case–control | 100 | 68 ± 9.0 66 ± 8.0 | Spine, knee | Radiographs | 7 | VAS | Alendronate VS Calcium |
Buckland-Wright (2007) | Double-blind randomized | 627 | 60.3 ± 2.6 63.1 ± 2.3 | Knee | Radiographs | 24 | JSW | Risedronate VS placebo |
Bingham et al. (2006) | Double-blind randomized | 2483 | 60.7 ± 0.5 60.2 ± 0.5 | Knee | Radiographs | 24 | WOMAC, JSW, | Risedronate VS placebo |
Spector et al. (2005) | Double-blind randomised | 285 | 63.8 ± 0.9 63.2 ± 0.8 | Knee | Radiographs | 12 | WOMAC; PGA | Risedronate VS placebo |
Carbone et al. (2004) | Cross sectional cohort study | 818 | 74.8 ± 2.9 74.8 ± 2.9 | Knee | Radiographs | 36 | Modified WOMAC | Alendronate VS placebo |
Fujita et al. (2001) | Non-blinded randomised, | 80 | 65 ± 7 | Spine, knee | Radiographs | 12 | VAS | Etidronate VAS placebo |